{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:40:22Z","timestamp":1762864822230,"version":"3.37.3"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1124\/jpet.104.069138","type":"journal-article","created":{"date-parts":[[2004,10,14]],"date-time":"2004-10-14T00:33:12Z","timestamp":1097713992000},"page":"502-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Inhibition of Epidermal Growth Factor Receptor Activity by Two Pyrimidopyrimidine Derivatives"],"prefix":"10.1016","volume":"311","author":[{"given":"Flavio F.","family":"Solca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Baum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Langkopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Dahmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Heinz","family":"Heider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Himmelsbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques C.A.","family":"van Meel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.104.069138_bib1","unstructured":"Arteaga CL (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19 (Suppl 18): 32S\u201340S."},{"key":"10.1124\/jpet.104.069138_bib2","doi-asserted-by":"crossref","unstructured":"Carpenter G (2000) The EGF receptor: a nexus for trafficking and signaling. Bioessays 22: 697\u2013707.","DOI":"10.1002\/1521-1878(200008)22:8<697::AID-BIES3>3.0.CO;2-1"},{"key":"10.1124\/jpet.104.069138_bib3","doi-asserted-by":"crossref","unstructured":"Carraway KL 3rd and Cantley LC (1994) A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78: 5\u20138.","DOI":"10.1016\/0092-8674(94)90564-9"},{"key":"10.1124\/jpet.104.069138_bib4","doi-asserted-by":"crossref","unstructured":"Dittrich C, Greim G, Borner M, Weigang-K\u00f6hler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, and Fumoleau P (2002) Phase I and pharmacokinetic study of BIBX1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 38: 1072\u20131080.","DOI":"10.1016\/S0959-8049(02)00020-5"},{"key":"10.1124\/jpet.104.069138_bib5","unstructured":"Fan Z, Baselga J, Masui H, and Mendelsohn J (1993) Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637\u20134642."},{"key":"10.1124\/jpet.104.069138_bib6","doi-asserted-by":"crossref","unstructured":"Fernandes A, Hamburger AW, and Gerwin BI (1999) ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer 83: 564\u2013570.","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q"},{"key":"10.1124\/jpet.104.069138_bib7","doi-asserted-by":"crossref","unstructured":"Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, et al. (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 95: 12022\u201312027.","DOI":"10.1073\/pnas.95.20.12022"},{"key":"10.1124\/jpet.104.069138_bib8","unstructured":"Gibson KH (1996) inventor, Zeneca Limited, UK, assignee. Quinazoline derivatives. Worldwide patent WO9633980. 1996 Oct 31."},{"key":"10.1124\/jpet.104.069138_bib9","doi-asserted-by":"crossref","unstructured":"Grunwald V and Hidalgo M (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851\u2013867.","DOI":"10.1093\/jnci\/95.12.851"},{"key":"10.1124\/jpet.104.069138_bib10","doi-asserted-by":"crossref","unstructured":"Gullick WJ (1991) Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87\u201398.","DOI":"10.1093\/oxfordjournals.bmb.a072464"},{"key":"10.1124\/jpet.104.069138_bib11","unstructured":"Heider KH, Dammrich J, Skroch-Angel P, Muller-Hermelink HK, Vollmers HP, Herrlich P, and Ponta H (1993a) Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 53: 4197\u20134203."},{"key":"10.1124\/jpet.104.069138_bib12","doi-asserted-by":"crossref","unstructured":"Heider KH, Hofmann M, Hors E, Van den BF, Ponta H, Herrlich P, and Pals ST (1993b) A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 120: 227\u2013233.","DOI":"10.1083\/jcb.120.1.227"},{"key":"10.1124\/jpet.104.069138_bib13","unstructured":"Himmelsbach F, Von Rueden T, Dahmann G, and Metz T (1997) inventors, Boehringer Ingelheim Pharma KG, assignee. Pyrimido[5,4-d]pyrimidines, medicaments containing these compounds, their use and process for production. Worldwide patent WO9732880. 1997 Sep 12."},{"key":"10.1124\/jpet.104.069138_bib14","doi-asserted-by":"crossref","unstructured":"Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, and Yarden Y (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15: 254\u2013264.","DOI":"10.1002\/j.1460-2075.1996.tb00356.x"},{"key":"10.1124\/jpet.104.069138_bib15","doi-asserted-by":"crossref","unstructured":"Klapper LN, Kirschbaum MH, Sela M, and Yarden Y (2000) Biochemical and clinical implications of the ErbB\/HER signaling network of growth factor receptors. Adv Cancer Res 77: 25\u201379.","DOI":"10.1016\/S0065-230X(08)60784-8"},{"key":"10.1124\/jpet.104.069138_bib16","doi-asserted-by":"crossref","unstructured":"Mendelsohn J and Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787\u20132799.","DOI":"10.1200\/JCO.2003.01.504"},{"key":"10.1124\/jpet.104.069138_bib17","doi-asserted-by":"crossref","unstructured":"Modjtahedi H, Affleck K, Stubberfield C, and Dean C (1998) EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 13: 335\u2013342.","DOI":"10.3892\/ijo.13.2.335"},{"key":"10.1124\/jpet.104.069138_bib18","doi-asserted-by":"crossref","unstructured":"Modjtahedi H and Dean C (1994) The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (review). Int J Oncol 4: 277\u2013296.","DOI":"10.3892\/ijo.4.2.277"},{"key":"10.1124\/jpet.104.069138_bib19","doi-asserted-by":"crossref","unstructured":"Nelson JM and Fry DW (2001) Akt, MAPK (Erk1\/2) and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 276: 14842\u201314847.","DOI":"10.1074\/jbc.M008786200"},{"key":"10.1124\/jpet.104.069138_bib20","doi-asserted-by":"crossref","unstructured":"Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, et al. (1999) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291: 739\u2013748.","DOI":"10.1016\/S0022-3565(24)35162-6"},{"key":"10.1124\/jpet.104.069138_bib21","doi-asserted-by":"crossref","unstructured":"Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, and Bloom KJ (2003) The HER-2\/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307\u2013325.","DOI":"10.1634\/theoncologist.8-4-307"},{"key":"10.1124\/jpet.104.069138_bib22","unstructured":"Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, et al. (2001) The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85\u201394."},{"key":"10.1124\/jpet.104.069138_bib23","doi-asserted-by":"crossref","unstructured":"Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, and Harris AL (1987) Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1: 1398\u20131402.","DOI":"10.1016\/S0140-6736(87)90593-9"},{"key":"10.1124\/jpet.104.069138_bib24","unstructured":"Shawver LK (1999) Tyrosine kinase inhibitors: from the emergence of targets to their clinical development, in American Society of Clinical Oncology 1999 Educational Book (Perry MC ed) pp 29\u201347, American Society of Clinical Oncology, Alexandria, VA."},{"key":"10.1124\/jpet.104.069138_bib25","unstructured":"Sirotnak FM, Zakowski MF, Miller VA, Scher HI, and Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coad-ministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885\u20134892."},{"key":"10.1124\/jpet.104.069138_bib26","doi-asserted-by":"crossref","unstructured":"Slichenmyer WJ, Elliott WL, and Fry DW (2001) CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 28: 80\u201385.","DOI":"10.1016\/S0093-7754(01)90285-4"},{"key":"10.1124\/jpet.104.069138_bib27","doi-asserted-by":"crossref","unstructured":"Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Showalter HD, Vincent PW, Elliott WL, et al. (2000) Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem 43: 1380\u20131397.","DOI":"10.1021\/jm990482t"},{"key":"10.1124\/jpet.104.069138_bib28","doi-asserted-by":"crossref","unstructured":"Sridhar SS, Seymour L, and Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4: 397\u2013406.","DOI":"10.1016\/S1470-2045(03)01137-9"},{"key":"10.1124\/jpet.104.069138_bib29","unstructured":"Stratowa C, Baum A, Castanon MJ, Dahmann G, Himmelsbach F, Himmler A, Loeber G, Metz T, Schnitzer R, Solca F, et al. (1999) A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity. Anticancer Drug Des 14: 393\u2013402."},{"key":"10.1124\/jpet.104.069138_bib30","doi-asserted-by":"crossref","unstructured":"Traxler P (2003) Tyrosine kinases as targets in cancer therapy\u2013successes and failures. Expert Opin Ther Targets 7: 215\u2013234.","DOI":"10.1517\/eott.7.2.215.23784"},{"key":"10.1124\/jpet.104.069138_bib31","doi-asserted-by":"crossref","unstructured":"Ullrich A and Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203\u2013212.","DOI":"10.1016\/0092-8674(90)90801-K"},{"key":"10.1124\/jpet.104.069138_bib32","doi-asserted-by":"crossref","unstructured":"van der Geer P, Hunter T, and Lindberg RA (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10: 251\u2013337.","DOI":"10.1146\/annurev.cb.10.110194.001343"},{"key":"10.1124\/jpet.104.069138_bib33","doi-asserted-by":"crossref","unstructured":"Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, Rosfjord EC, Discafani C, Davis R, Shi X, et al. (2003) Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem 46: 49\u201363.","DOI":"10.1021\/jm020241c"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524316210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524316210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.104.069138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:03:43Z","timestamp":1739999023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524316210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S0022356524316210"],"URL":"https:\/\/doi.org\/10.1124\/jpet.104.069138","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2004,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Epidermal Growth Factor Receptor Activity by Two Pyrimidopyrimidine Derivatives","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.104.069138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}